$7.1 Billion in Six Months: Isomorphic Labs Builds Toward Its First Human Trials

Isomorphic Labs raised $5 billion to expand its AI drug design platform and move its first drug candidates toward human trials after a $2.1 billion May round.

Nov 20, 2026
$7.1 Billion in Six Months: Isomorphic Labs Builds Toward Its First Human Trials

AI drug discovery startup Isomorphic Labs raises record $5 billion. Image: Isomorphic

AI has already learned to predict how proteins fold. Now Isomorphic Labs wants to turn that knowledge into medicines, and investors are putting $5 billion behind the idea.

The Alphabet-backed company announced a $5 billion Series C funding round on Nov. 17, co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz (a16z) and several other new investors joined, while Alphabet and all existing investors also participated.

The financing follows a $2.1 billion Series B round in May, giving Isomorphic two multibillion-dollar raises in roughly six months. The company has not disclosed its latest valuation.

Founded in 2021 as a spinout from Google DeepMind, Isomorphic is led by CEO Demis Hassabis, who recently stepped back from running DeepMind to focus on his drug discovery venture.

IsoDDE is at the center of the company’s ambitions

Isomorphic plans to use the new capital to develop its proprietary drug design engine, IsoDDE, and advance its existing medicine candidates toward clinical trials.

Advertisement

The platform combines simulation-based AI models that help researchers explore chemical possibilities, predict molecular behavior and refine potential drug candidates before laboratory testing.

The company says its technology has produced positive preclinical results in internal oncology and immunology programs, as well as projects developed with pharmaceutical partners. Those partners include Eli Lilly, Novartis and Johnson & Johnson.

Isomorphic also plans to expand its research into new areas of biology and build infrastructure to support clinical development and AI-led bioengineering.

The funding arrives as pharmaceutical companies increasingly invest in AI to accelerate drug discovery. However, Isomorphic still needs to show that its AI-designed candidates can become safe, effective medicines.

No AI-designed medicine has been approved by regulators, and promising preclinical results do not guarantee success in human trials.

That distinction matters because drug development involves more than identifying promising molecules. Candidates must survive extensive testing for safety, effectiveness and potential side effects.

Advertisement

Isomorphic’s biggest opportunity is reducing the time researchers spend searching for viable drug candidates. But its technology must deliver results beyond computer predictions before that promise becomes commercially meaningful.

More must-read AI coverage

What this means for patients and the pharmaceutical industry

Patients should not expect new medicines to appear immediately because of this funding. However, if Isomorphic’s approach succeeds, its technology could help researchers identify promising treatments for diseases that have proved difficult to tackle using conventional discovery methods.

For pharmaceutical companies, the investment could also strengthen AI-driven drug development, creating opportunities for partnerships with technology companies rather than relying entirely on traditional research methods.

Advertisement

The next major milestone will be moving Isomorphic’s first candidates into human clinical trials. That is where investors, pharmaceutical partners and patients will get a clearer picture of whether its expensive AI infrastructure can deliver actual medical breakthroughs.

Other news: Singapore-based Actxa opened preorders for its Spark Band, a screenless fitness tracker that uses AI and wrist sensors to estimate blood sugar in about a minute for general wellness.

Aminu Abdullahi

Aminu Abdullahi is a B2C and B2B technology and finance writer with more than six years of experience covering enterprise IT, cybersecurity, cloud computing, artificial intelligence, fintech, business software, and emerging technologies. He has written for a wide range of technical and business audiences, from IT professionals and cybersecurity leaders to small business owners, executives, and technology buyers. His work has appeared in publications including: TechRepublic eWEEK Channel Insider Geekflare Enterprise Networking Planet eSecurity Planet CIO Insight Webopedia With a background in computer science, Aminu specializes in translating complex technical subjects into clear, practical, and accessible content. His writing helps readers understand emerging technologies, evaluate business software, strengthen cybersecurity strategies, and make more informed decisions about technology investments. Across his work, Aminu focuses on the real-world impact of technology, connecting technical innovation with business value, operational efficiency, security, and long-term digital transformation.